Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px
Organisation › Details

Lava Therapeutics B.V.

Lava Therapeutics’ proprietary platform is focused on developing next generation ?d T cell engaging bispecific antibodies to treat cancer. Our first-in-class immuno-oncology approach activates V?9Vd2 T cells upon binding to membrane-expressed tumor targets. Lava’s vision is to develop therapeutics for the curative treatment of cancer. Founded in 2016, Lava Therapeutics is advancing cutting-edge research originating from the group of Dr. Hans van der Vliet at the VU University Medical Center and Cancer Center Amsterdam. *

 

Period Start 2016-01-01 established
Products Industry gamma-delta T cell engager
  Industry 2 immunomodulatory cancer drug
     
Region Region ’s-Hertogenbosch (den Bosch)
  Country Netherlands
  Street 225 Onderwijsboulevard
  City 5223 DE ’s-Hertogenbosch
  Tel +31-8-506-57344
    Address record changed: 2018-05-25
     
Basic data Employees n. a.
     
    * Document for �About Section�: Lava Therapeutics B.V.. (5/23/18). "Press Release: Lava Therapeutics Raises EUR 16 Million to Advance Bispecific Gamma-Delta T Cell Engager Platform. Biologics Expert Paul Parren Joins as Head of R&D". ’s Hertogenbosch.
     
   
Record changed: 2019-08-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

More documents for Lava Therapeutics B.V.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px




» top